Clinical Trials

Lymphoma, Follicular

NCT06191887 2026-02-13

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Phase 1 Recruiting

27 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04223765 2026-01-20

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Phase 1 Recruiting

20 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02996773 2025-11-10

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

LymphoidMyeloidOther hematologic neoplasmSarcoma

50 enrolled

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Mycobacterium avium-intracellulare Infection, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

NCT01479842 2025-10-15

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Phase 1 Active not recruiting

48 enrolled

Phase 1 Active not recruiting

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02153580 2025-10-06

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

37 enrolled

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT07126678 2025-08-17

Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

Phase NA Recruiting

15 enrolled

Lymphoma, Follicular

NCT04587687 2025-04-24

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Phase 2 Recruiting

23 enrolled

Phase 2 Not yet recruiting

Lymphoma, Follicular

NCT06757894 2025-01-03

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

50 enrolled

Lymphoma, Follicular

NCT06284122 2024-10-15

MorningLyte

Phase 3 Recruiting

790 enrolled

Lymphoma, Follicular

NCT00991211 2024-08-22

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Phase 3 Completed

549 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05848765 2023-11-29

REFRACT

Phase 2 Recruiting

284 enrolled

Lymphoma, Lymphoma, Follicular

NCT05899621 2023-06-12

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting

332 enrolled

Lymphoma, Lymphoma, Follicular

NCT02257242 2023-02-09

BRiM

11 enrolled 20 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02063685 2022-06-21

Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma

Phase 3 Completed

807 enrolled

Lymphoma, Follicular

NCT04934930 2021-06-22

FLMRD

Phase 2 Unknown

40 enrolled

Lymphoma, Follicular

NCT01234766 2021-05-18

Fol-BRITe

Phase 2 Completed

39 enrolled 6 charts

Lymphoma, Follicular

NCT00901927 2020-04-03

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Phase 2 Terminated

14 enrolled 10 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT01429025 2019-10-08

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

26 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT00987493 2019-05-15

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

Phase 1/2 Completed

49 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02008006 2019-01-08

BENEFIT

Phase 2 Terminated

21 enrolled

Lymphoma, Follicular

NCT02240719 2019-01-04

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

LymphoidOther hematologic neoplasmPlasma cell

20 enrolled

Hodgkin Disease, Lymphoma, Follicular, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02168907 2018-07-02

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1 Terminated

1 enrolled

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT01313611 2018-03-07

BRIEF

Phase 2 Terminated

62 enrolled

Lymphoma, Follicular

NCT01078142 2017-09-11

BERT

Phase 1/2 Completed

39 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Follicular, Lymphoma, Mantle-Cell

NCT01110135 2017-05-24

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma

Phase 2 Completed

43 enrolled 5 charts

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT02623920 2017-05-19

S-BR

Phase 2 Withdrawn

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT01523860 2016-03-01

FLE09

Phase 2 Completed

76 enrolled

Lymphoma, Follicular

NCT02134262 2014-11-06

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Phase 1/2 Unknown

18 enrolled